SYNACT SynAct Pharma AB (publ)

1.282USD13.00 SEK · STO-0.91%Mkt Cap: 71.79M USDP/E: —

SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical t…

Key Statistics

Company
Market Cap71.79M USD
Enterprise Value72.10M USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-10.93M USD
Revenue/Share—
Last Price1.282 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees8
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0008241491
Valuation
P/E (Trailing)—
P/E (Forward)-7.30
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.13
EPS (TTM)-0.18 USD
EPS (Forward)-0.18 USD
52W Range
0.695234% of range2.416
52W High2.416 USD
52W Low0.6952 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-65.08%
ROA-50.26%
ROIC-91.71%
ROCE-59.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.60M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-10.78%
Net Debt312.20K USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.01
Current Ratio4.79
Quick Ratio4.69
Book Value/Sh0.25 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.885 USD
Upside (mean)+203.1%
Target Range3.885 USD – 3.885 USD
# Analysts1
Ownership
Shares Out.56.00M
Float37.83M
Insiders25.30%
Institutions19.40%
Technical
SMA 501.661 (-22.8%)
SMA 2001.710 (-25.0%)
Beta0.84
S&P 52W Chg8.68%
Avg Vol (30d)148.37K
Avg Vol (10d)246.04K
Technical Indicators
RSI (14)32.0
MACD-1.0561
MACD Signal-0.8351
MACD Hist.-0.2210
BB Upper1.819 USD
BB Middle1.509 USD
BB Lower1.199 USD
BB Width41.09%
ATR (14)0.1221 USD
Vol Ratio (20d)0.65x

About SynAct Pharma (STO: SYNACT)

›

SynAct Pharma (STO: SYNACT) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.

The shares were at 13.00 SEK on 20 November 2026, down 40.2% over 52 weeks. Its 52-week range is 7.050 SEK to 24.50 SEK: the price is 46.9% below the high and 84.4% above the low.

Its market capitalisation is 727.98M SEK.

SynAct Pharma reports return on equity of -65.1% and an operating margin of 0.0%.

Its debt exceeds its cash by 3.17M SEK, a debt-to-equity ratio of 0.01. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 39.40 SEK is 203.1% above the current price.